COVID-19后肺疾病:生化和影像标志物在揭示残余肺部炎症及监测抗炎治疗中的效用,一项前瞻性研究
这项前瞻性研究纳入30例重症COVID-19肺炎后患者,基线18F-FDG PET/CT显示所有患者存在残余肺部炎症(平均SUVmax 3.8±2.3,累及肺段数8±3),CT严重度评分平均17.7±3.4。接受吡非尼酮和甲泼尼龙治疗6-12周后,97%患者影像分级改善,疾病范围(肺段数)和严重度(FDG摄取)显著下降,临床和影像学改善伴炎症标志物下降(p<0.005)。血清铁蛋白和总白细胞计数与18F-FDG PET/CT所示PCLD严重度显著相关(p<0.05)。
要点
- 基线18F-FDG PET/CT显示所有COVID-19后肺疾病患者存在残余肺部炎症,平均SUVmax为3.8±2.3
- 抗炎和抗纤维化治疗6-12周后97%患者影像分级改善,FDG摄取和累及肺段数显著下降
- 血清铁蛋白和总白细胞计数与18F-FDG PET/CT所示疾病严重度显著相关(p<0.05)
核心结论
- 本研究在18F-FDG PET/CT上识别并量化了COVID-19后肺疾病中持续存在的显著残余肺部炎症。
- 抗炎和抗纤维化药物治疗带来了临床和影像学改善。
- 18F-FDG PET/CT作为无创生物标志物有助于COVID-19后肺疾病患者的管理和随访。
研究设计与样本
- 前瞻性研究,纳入30例重症COVID-19肺炎后患者。
- 患者接受基线18F-FDG PET/CT扫描以显示FDG和CT上的残余肺部炎症病灶。
- 患者接受抗纤维化药物(吡非尼酮)和抗炎药物(甲泼尼龙)治疗6-12周。
- 随访评估临床、生化和影像学治疗反应。
主要发现
- 基线18F-FDG PET/CT显示所有COVID-19后肺疾病患者存在持续肺部炎症,平均SUVmax为3.8±2.3,累及肺段数为8±3。
- 平均CT严重度评分为17.7±3.4,疾病累及程度为中度(n=16)或重度(n=14)。
- 18F-FDG PET/CT分级为轻度、中度和重度者分别为8例、14例和8例。
- 治疗后PET扫描显示疾病范围(肺段数)和严重度(FDG摄取)显著下降,影像学疾病分级改善(97%患者)。
- 与PET结果一致,临床和影像学显著改善,炎症标志物下降(p<0.005);血清铁蛋白和总白细胞计数与18F-FDG PET/CT所示COVID-19后肺疾病严重度显著相关(p<0.05)。
关键数值与推荐
- 基线平均SUVmax为3.8±2.3,累及肺段数为8±3。
- 平均CT严重度评分为17.7±3.4,中度疾病16例,重度疾病14例。
- 18F-FDG PET/CT分级:轻度8例,中度14例,重度8例。
- 治疗后97%患者影像学疾病分级改善。
- 炎症标志物下降的p值<0.005;血清铁蛋白和总白细胞计数与疾病严重度相关的p值<0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Post-COVID-19 lung disease (PCLD) is a significant concern following the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. PCLD encompasses persistent debilitating respiratory symptoms and radiological changes beyond the acute disease phase. It highlights the ongoing search to identify and manage lingering diseases. This prospective study utilizes F18-Fludeoxyglucose (FDG) PET/CT to identify residual inflammatory lung lesions in PCLD. Treatment response was assessed after anti-inflammatory and antifibrotic therapies. MATERIALS AND METHODS: Thirty patients post-severe COVID-19 pneumonia enrolled. They underwent baseline 18F-FDG PET/CT scans to unveil residual lung inflammation lesions on FDG and CT. They received antifibrotic (Pirfenidone) and anti-inflammatory (Methylprednisolone) drugs for 6-12 weeks. They were followed up for clinical, biochemical, and imaging treatment responses. RESULTS: Baseline 18F-FDG PET/CT revealed ongoing lung inflammation in all PCLD (mean SUVmax: 3.8 ± 2.3 and number of segments: 8±3 ). The mean CT severity score was 17.7 ± 3.4 with moderate (n = 16) or severe (n = 14) disease involvement. Mild, moderate, and severe 18F-FDG PET/CT categories were noted in the 8, 14, and 8 patients, respectively. Following treatment, a PET scan showed a significant decrease in disease extent (segments) and severity (FDG uptake) and an improvement in disease grading on imaging (97% of patients). In PET concordance, there was a significant clinical and radiological improvement with a fall in inflammatory markers (p < 0.005). Serum Ferritin and total leukocyte counts were significantly associated with PCLD severity on 18F-FDG PET/CT(p < 0.05). CONCLUSION: This prospective study identifies and quantifies ongoing significant residual lung inflammation in PCLD on 18F-FDG PET/CT. Anti-inflammatory and antifibrotic drug therapy led to clinical and radiological improvement. 18F-FDG PET/CT as a non-invasive biomarker helped manage and follow up PCLD patients. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Khandelwal Y, Ora M, Jain B, et al. Post-COVID-19 lung disease: utility of biochemical and imaging markers in uncovering residual lung inflammation and monitoring anti-inflammatory therapy, a prospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40355745. doi:10.1007/s00259-025-07297-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。